Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cyt.12329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of Crohn's Disease With Infliximab and Subsequent Development of Takayasu's Arteritis.
Gastroenterology Res
December 2024
Department of Gastroenterology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
A 23-year-old man was diagnosed with Crohn's disease (CD) of the large intestine after colonoscopy revealed longitudinal ulcers, and pathology revealed non-caseating epithelioid cell granulomas and anal fistulas. The CD relapsed, and therefore prednisolone (PSL) and infliximab (IFX) treatment was initiated. The PSL was gradually tapered.
View Article and Find Full Text PDFNovel Therapeutics in Soft Tissue Sarcoma.
Cancers (Basel)
December 2024
Sarcoma Unit, The Royal Marsden Hospital and Institute of Cancer Research, London SW3 6JZ, UK.
There has been noteworthy progress in molecular characterisation and therapeutics in soft tissue sarcomas. Novel agents have gained regulatory approval by the FDA. Examples are the tyrosine kinase inhibitors avapritinib and ripretinib in gastrointestinal stromal tumours (GIST), the immune check point inhibitor atezolizumab in alveolar soft part tissue sarcoma, the γ-secretase inhibitor nirogacestat in desmoid tumours, the NTRK inhibitors larotrectinib and entrectinib in tumours with fusions, the mTOR inhibitor nab-sirolimus in PEComa, and the EZH-2 inhibitor tazemetostat in epithelioid sarcoma.
View Article and Find Full Text PDFA first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
Eur J Cancer
November 2024
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Purpose: MAK683, a first-in-class and highly selective allosteric inhibitor of the embryonic ectoderm development subunit of polycomb repressive complex 2, has shown sustained antitumor activity in tumor xenograft models. This first-in-human phase 1/2 study evaluated the safety, pharmacokinetics (PK), and clinical activity of single-agent MAK683 in advanced malignancies.
Methods: MAK683 was administered fasted once daily or twice daily continuously in 28-day treatment cycles.
Multiple sarcomatoid carcinoma of the small intestine with perforation as the initial symptom: case report and review of the literature.
Front Oncol
December 2024
Department of Gastrointestinal Surgery, Weihai Central Hospital, Qingdao University, Weihai, Shandong, China.
Background: Sarcomatoid carcinoma of the small bowel is an exceedingly rare gastrointestinal tumor characterized by a biphasic cellular pattern of epithelioid and mesenchymal-like cells. Due to its rarity and non-specific clinical presentation, it is frequently misdiagnosed, and there is a lack of standardized management guidelines. We report a case of multiple sarcomatoid carcinoma of the small intestine, presenting initially with gastrointestinal perforation.
View Article and Find Full Text PDFThree novel neoplasms in Nancy Ma's owl monkeys ().
Vet Pathol
December 2024
The University of Texas MD Anderson Cancer Center, Bastrop, TX.
Neoplasms are only sporadically reported in New World primates and rarely in owl monkeys (), specifically. Previous reports of neoplasms in owl monkeys are primarily restricted to lymphoma induced by infection, although other tumors in the central nervous, genitourinary, gastrointestinal, and endocrine systems have been sporadically reported. Herein, we describe 3 previously unreported neoplasms in owl monkeys () including a pericardial mesothelioma in a 6-year-old male, a nephroblastoma in a 2-year-old male, and a cervical neoplasm with characteristics of an epithelioid trophoblastic tumor in a 4-year-old female, all occurring in the same closed breeding colony at a research facility in central Texas.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!